/
CLYM
$13.20+$0.28 (+2.14%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$749.0M
57M shares
52-week range
$1.19 – $13.59
97% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$8.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $97.0K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | −$97.0K |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $4.0M | $9.3M | $23.3M | $26.2M | $15.4M | $14.3M | $46.6M |
| Operating income | −$7.4M | −$20.9M | −$35.7M | −$45.1M | −$40.3M | −$82.0M | −$67.9M |
| EBITDA | −$4.7M | −$11.8M | −$47.5M | −$45.2M | −$35.1M | −$30.4M | −$59.8M |
| Net income | −$6.5M | −$20.7M | −$47.5M | −$45.2M | −$35.1M | −$73.9M | −$59.9M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.56 | -1.97 | -4.24 | -1.72 | -1.30 | -1.53 | -0.88 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.87 | $-1.17–$-0.70 | 10 |
| 2027 | $888890 | $-1.05 | $-1.37–$-0.81 | 10 |
| 2028 | $0 | $-1.44 | $-3.12–$-0.94 | 12 |
| 2029 | $209000 | $-1.91 | $-1.91–$-1.91 | 10 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.49
Price
$13.20
Implied downside
-96%
Peer comparison
Climb Bio, Inc. Common Stock
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
www.climbbio.com- Employees
- 29
- IPO / List date
- Aug 10, 2021
- HQ
- WELLESLEY HILLS, MA
Held by traders on TradeandTell
No one on the platform currently holds CLYM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 217,300 | $1.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CLYM yet.
